Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RGLS Stock Forecast 2025-2026
$7.92
Current Price
$550.41M
Market Cap
Buy 2
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to RGLS Price Targets
+38.9%
To High Target of $11.00
+13.6%
To Median Target of $9.00
-11.6%
To Low Target of $7.00
RGLS Price Momentum
+0.9%
1 Week Change
+241.4%
1 Month Change
+312.5%
1 Year Change
+407.7%
Year-to-Date Change
-3.4%
From 52W High of $8.20
+854.2%
From 52W Low of $0.83
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Regulus (RGLS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on RGLS and similar high-potential opportunities.
Latest RGLS Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, RGLS has a neutral consensus with a median price target of $9.00 (ranging from $7.00 to $11.00). The overall analyst rating is Buy (7.0/10). Currently trading at $7.92, the median forecast implies a 13.6% upside. This outlook is supported by 2 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Whitney Ijem at Canaccord Genuity, projecting a 38.9% upside. Conversely, the most conservative target is provided by Joseph Schwartz at Leerink Partners, suggesting a 11.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RGLS Analyst Ratings
2
Buy
4
Hold
0
Sell
RGLS Price Target Range
Low
$7.00
Average
$9.00
High
$11.00
Current: $7.92
Latest RGLS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RGLS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 1, 2025 | Wells Fargo | Yanan Zhu | Equal-Weight | Downgrade | $9.00 |
| Apr 30, 2025 | Leerink Partners | Joseph Schwartz | Market Perform | Downgrade | $7.00 |
| Apr 30, 2025 | Canaccord Genuity | Whitney Ijem | Hold | Downgrade | $11.00 |
| Apr 30, 2025 | Jones Trading | Catherine Novack | Hold | Downgrade | $7.00 |
| Mar 27, 2025 | Wells Fargo | Yanan Zhu | Overweight | Upgrade | $6.00 |
| Mar 17, 2025 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $28.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Feb 26, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Oct 30, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Oct 8, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Aug 14, 2024 | Oppenheimer | Andreas Argyrides | Outperform | Reiterates | $7.00 |
| Aug 9, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Jul 16, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Jun 25, 2024 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $28.00 |
| Jun 25, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $10.00 |
| May 31, 2024 | Jones Trading | Catherine Novack | Buy | Initiates | $8.00 |
| May 10, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $9.00 |
| May 6, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $9.00 |
| Mar 25, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $9.00 |
Regulus Therapeutics Inc. (RGLS) Competitors
The following stocks are similar to Regulus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Regulus Therapeutics Inc. (RGLS) Financial Data
Regulus Therapeutics Inc. has a market capitalization of $550.41M with a P/E ratio of -9.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -53.8%.
Valuation Metrics
Market Cap
$550.41M
Enterprise Value
$480.91M
P/E Ratio
-9.7x
PEG Ratio
-6.6x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+11.9%
Current Ratio
16.3x
Debt/Equity
2.0x
ROE
-53.8%
ROA
-34.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Regulus Therapeutics Inc. (RGLS) Business Model
About Regulus Therapeutics Inc.
What They Do
Develops medicines targeting microRNAs for diseases.
Business Model
Regulus Therapeutics operates by discovering and developing innovative microRNA-based therapies aimed at treating diseases with unmet medical needs. The company generates revenue primarily through partnerships, collaborations, and potentially from the commercialization of its therapies as they progress through clinical trials.
Additional Information
The company focuses on conditions such as genetic and fibrotic diseases and plays a significant role in advancing microRNA research, which may lead to groundbreaking therapeutic innovations. Its commitment to clinical trials and collaborations positions it as a key player in the biotechnology sector, particularly in personalized medicine and targeted treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
34
CEO
Mr. Joseph P. Hagan M.B.A.
Country
United States
IPO Year
2012
Website
www.regulusrx.comRegulus Therapeutics Inc. (RGLS) Latest News & Analysis
Latest News
Quick Summary
Regulus Therapeutics has agreed to be acquired by Novartis for $7.00 per share, potentially totaling $1.7 billion with CVR. Completion expected in H2 2025, pending regulatory milestones.
Why It Matters
Novartis' acquisition of Regulus for up to $14 per share enhances investor confidence by validating Regulus' pipeline, especially in treating ADPKD, and suggests potential future growth.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Regulus Therapeutics Inc. is set to be sold to Novartis AG for $7.00 per share in cash, plus a contingent value right for an additional $7.00 based on milestone achievements.
Why It Matters
The investigation into Regulus Therapeutics' sale to Novartis could indicate potential issues with the deal, impacting share value and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Novartis will acquire Regulus Therapeutics for up to $1.7 billion to access its experimental kidney disease drug, as announced by Regulus on Wednesday.
Why It Matters
Novartis' acquisition of Regulus Therapeutics enhances its pipeline in kidney disease treatments, potentially boosting future revenue and market position, impacting investor sentiment and stock performance.
Source: Reuters
Market Sentiment:
Positive
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS
21 days ago
Quick Summary
Monteverde & Associates PC is investigating Regulus Therapeutics Inc. (NASDAQ: RGLS) in connection with its proposed merger with Novartis AG, following a strong track record in shareholder recovery.
Why It Matters
The investigation into Regulus Therapeutics' merger with Novartis may indicate potential legal risks, affecting investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
The Ademi Firm is investigating Regulus (Nasdaq: RGLS) for potential fiduciary duty breaches related to its $0.8 billion cash transaction with Novartis, offering shareholders $7.00 per share.
Why It Matters
Regulus faces scrutiny over potential fiduciary breaches in its deal with Novartis, potentially impacting shareholder value and investor confidence in the company's governance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Halper Sadeh LLC is investigating the fairness of Regulus Therapeutics' sale to Novartis for $7.00 per share, plus potential additional payments tied to regulatory milestones.
Why It Matters
The investigation into Regulus' sale to Novartis could impact share prices and investor sentiment, particularly regarding the fairness of the cash offer and potential future payouts.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About RGLS Stock
What is Regulus Therapeutics Inc.'s (RGLS) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Regulus Therapeutics Inc. (RGLS) has a median price target of $9.00. The highest price target is $11.00 and the lowest is $7.00.
Is RGLS stock a good investment in 2025?
According to current analyst ratings, RGLS has 2 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.92. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RGLS stock?
Wall Street analysts predict RGLS stock could reach $9.00 in the next 12 months. This represents a 13.6% increase from the current price of $7.92. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Regulus Therapeutics Inc.'s business model?
Regulus Therapeutics operates by discovering and developing innovative microRNA-based therapies aimed at treating diseases with unmet medical needs. The company generates revenue primarily through partnerships, collaborations, and potentially from the commercialization of its therapies as they progress through clinical trials.
What is the highest forecasted price for RGLS Regulus Therapeutics Inc.?
The highest price target for RGLS is $11.00 from Whitney Ijem at Canaccord Genuity, which represents a 38.9% increase from the current price of $7.92.
What is the lowest forecasted price for RGLS Regulus Therapeutics Inc.?
The lowest price target for RGLS is $7.00 from Joseph Schwartz at Leerink Partners, which represents a -11.6% decrease from the current price of $7.92.
What is the overall RGLS consensus from analysts for Regulus Therapeutics Inc.?
The overall analyst consensus for RGLS is neutral. Out of 12 Wall Street analysts, 2 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $9.00.
How accurate are RGLS stock price projections?
Stock price projections, including those for Regulus Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 22, 2025 4:19 AM UTC